Filing Flows

Filing Flows › Arcutis Biotherapeutics (ARQT) › How it makes money

How Arcutis Biotherapeutics (ARQT) makes money

Arcutis Biotherapeutics (ARQT) made $144M of revenue in the third quarter 2026 (Q3 2026), +45% from a year earlier. ZORYVE foam brought in $75.1M (52%); ZORYVE cream 0.3% brought in $37.8M (26%); ZORYVE cream 0.15% brought in $27.3M (19%). Of every dollar of revenue, 7¢ was left as operating profit, 6¢ was left as net earnings.

Drawing the Sankey…

Arcutis Biotherapeutics revenue by segment, Q3 2026Arcutis Biotherapeutics revenue by segment, Q3 2026ZORYVE foam$75.1MZORYVE cream 0.3%$37.8MZORYVE cream 0.15%$27.3MZORYVE cream 0.05%$3.7M
Arcutis Biotherapeutics: revenue by line, Q1 2025 to Q3 2026Arcutis Biotherapeutics: revenue by line, Q1 2025 to Q3 2026ZORYVE foamZORYVE cream 0.3%ZORYVE cream 0.15%ZORYVE cream 0.05%Other revenuesZORYVE foam: $75.1M latest$75.1MZORYVE cream 0.3%: $37.8M latest$37.8MZORYVE cream 0.15%: $27.3M latest$27.3MZORYVE cream 0.05%: $3.7M latestOther revenues: $0 latestQ1 2025Q2 2025Q3 2025Q1 2026Q2 2026Q3 2026
ZORYVE cream 0.3% went from 36% of revenue in Q1 2025 to 26% in Q3 2026, the largest shift in the mix.
Arcutis Biotherapeutics revenue by quarterArcutis Biotherapeutics revenue by quarter$65.8MQ1 2025$81.5MQ2 2025$99.2MQ3 2025$130MQ4 2025$105MQ1 2026$130MQ2 2026$144MQ3 2026
Arcutis Biotherapeutics: where each dollar of revenue goesArcutis Biotherapeutics: where each dollar of revenue goesOperating profit7¢Income tax0¢Net earnings6¢Operating cash flow13¢Free cash flow13¢

Revenue by segment, Q3 2026

SegmentRevenueShareQ/QY/Y
ZORYVE foam$75.1M52.2%+12%+51%
ZORYVE cream 0.3%$37.8M26.2%+7%+24%
ZORYVE cream 0.15%$27.3M18.9%+13%+44%
ZORYVE cream 0.05%$3.7M2.6%+28%—

Where each dollar of revenue goes

LineQ3 2026% of revenue
Revenue$144M100.0%
Operating profit$9.4M6.6%
Income tax$195K0.1%
Net earnings$8.8M6.1%
Operating cash flow$18.9M13.1%
Free cash flow$18.8M13.1%

Revenue, quarter by quarter

QuarterRevenueY/Y
Q3 2026$144M+45%
Q2 2026$130M+59%
Q1 2026$105M+60%
Q4 2025$130M+82%
Q3 2025$99.2M+122%
Q2 2025$81.5M+164%
Q1 2025$65.8M+33%

From Arcutis Biotherapeutics' 10-Q filed Nov 4, 2026 (on EDGAR).

Questions

How does Arcutis Biotherapeutics make money?

Arcutis Biotherapeutics (ARQT) made $144M of revenue in the third quarter 2026 (Q3 2026), +45% from a year earlier. ZORYVE foam brought in $75.1M (52%); ZORYVE cream 0.3% brought in $37.8M (26%); ZORYVE cream 0.15% brought in $27.3M (19%). Of every dollar of revenue, 7¢ was left as operating profit, 6¢ was left as net earnings.

What is Arcutis Biotherapeutics' biggest business?

ZORYVE foam: $75.1M in the third quarter 2026, 52% of revenue, +51% from a year earlier.

What is Arcutis Biotherapeutics' profit margin?

Net earnings were $8.8M, 6.1% of revenue, in the third quarter 2026; the operating margin was 6.6%.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.